Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 17/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275906 | 0.90 | ADORA2B (0.37) | CRHR1ADORA2BALDH1A1NPSR1 | |
| SCHEMBL10276011 | 0.89 | ARF6 (0.41) | CRHR1ADORA2BALDH1A1NPSR1 | |
| SCHEMBL10275898 | 0.85 | ADORA2B (0.39) | ADORA2B | |
| SCHEMBL10275796 | 0.78 | CYP3A4 (0.41) | CRHR1ALDH1A1NPSR1 | |
| SCHEMBL10276006 | 0.78 | ARF6 (0.40) | CRHR1 | |
| SCHEMBL12826214 | 0.77 | CRHR1 (0.37) | CRHR1ALDH1A1 | |
| SCHEMBL10313567 | 0.75 | CHRNA7 (0.37) | ADORA2BALDH1A1 | |
| SCHEMBL10275647 | 0.74 | ADORA2B (0.38) | ADORA2BALDH1A1NPSR1 | |
| SCHEMBL10276570 | 0.73 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL10276119 | 0.72 | ARF6 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | CRHR1 1464/4885ADORA2B 86/4885ALDH1A1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.